The antimalarial drugs chloroquine and primaquine inhibit pyridoxal kinase, an essential enzyme for vitamin B6 production
| Autor: | Ryutaro Shirakawa, Takashi Hayashi, Keisuke Nagano, Hisanori Horiuchi, Tomohiro Kimura, Nobuhiro Yaoita |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Primaquine
Trypanosoma cruzi Protozoan Proteins Biophysics Pharmacology Biochemistry Substrate Specificity Antimalarials chemistry.chemical_compound Structural Biology Chloroquine parasitic diseases Pyridoxal kinase Genetics medicine Humans Enzyme Inhibitors Molecular Biology Pyridoxal chemistry.chemical_classification Kinase Binding protein Cell Biology medicine.disease Malaria Enzyme chemistry Plasmodium vivax HeLa Cells Protein Binding medicine.drug |
| Zdroj: | FEBS Letters. 588:3673-3676 |
| ISSN: | 0014-5793 |
| DOI: | 10.1016/j.febslet.2014.08.011 |
| Popis: | Quinoline derivatives such as chloroquine and primaquine are widely used for the treatment of malaria. These drugs are also used for the treatment of trypanosomiasis, and more recently for cancer therapy. However, molecular target(s) of these drugs remain unclear. In this study, we have identified human pyridoxal kinase as a binding protein of primaquine. Primaquine inhibited pyridoxal kinases of malaria, trypanosome and human, while chloroquine inhibited only malaria pyridoxal kinase. Thus, we have identified pyridoxal kinase as a possible target molecule of the antimalarial drugs chloroquine and primaquine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text